1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Aging-associated	_	_	JJ	_	_	_	_	_
2	disabilities	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	generated	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	accumulation	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	randomly	_	_	RB	_	_	_	_	_
10	occurring	_	_	VBG	_	_	_	_	_
11	molecular	_	_	JJ	_	_	_	_	_
12	damages	_	_	NNS	_	_	_	_	_
13	during	_	_	IN	_	_	_	_	_
14	life	_	_	NN	_	_	_	_	_
15	time	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	affect	_	_	VBP	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	organism	_	_	NN	_	_	_	_	_
21	at	_	_	IN	_	_	_	_	_
22	multiple	_	_	JJ	_	_	_	_	_
23	levels	_	_	NNS	_	_	_	_	_
24	such	_	_	JJ	_	_	_	_	_
25	as	_	_	IN	_	_	_	_	_
26	metabolism	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	immune	_	_	JJ	_	_	_	_	_
29	response	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	repair	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	regeneration	_	_	NN	_	_	_	_	_
35	as	_	_	RB	_	_	_	_	_
36	well	_	_	RB	_	_	_	_	_
37	as	_	_	IN	_	_	_	_	_
38	altered	_	_	VBN	_	_	_	_	_
39	inter-	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	intracellular	_	_	JJ	_	_	_	_	_
42	communication	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Typical	_	_	JJ	_	_	_	_	_
2	alterations	_	_	NNS	_	_	_	_	_
3	detectable	_	_	JJ	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	aged	_	_	NN	_	_	_	_	_
6	tissues	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	increased	_	_	VBN	_	_	_	_	_
9	concentrations	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	reactive	_	_	JJ	_	_	_	_	_
12	oxygen	_	_	NN	_	_	_	_	_
13	species	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	ROS	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	concomitant	_	_	JJ	_	_	_	_	_
19	increased	_	_	VBN	_	_	_	_	_
20	DNA-damage	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	lipid	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	protein	_	_	NN	_	_	_	_	_
25	oxidation	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Often	_	_	RB	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	accompanied	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	accumulation	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	insoluble	_	_	JJ	_	_	_	_	_
9	protein	_	_	NN	_	_	_	_	_
10	aggregates	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	lipofuscin	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	at	_	_	IN	_	_	_	_	_
15	least	_	_	JJS	_	_	_	_	_
16	partially	_	_	RB	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	consequence	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	impaired	_	_	VBN	_	_	_	_	_
22	proteasome	_	_	NN	_	_	_	_	_
23	function	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	glycation	_	_	NN	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	reported	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	contribute	_	_	VB	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	limited	_	_	JJ	_	_	_	_	_
11	degradation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	function	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	proteins	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Glycation	_	_	NNP	_	_	_	_	_
2	represents	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	important	_	_	JJ	_	_	_	_	_
5	posttranslational	_	_	JJ	_	_	_	_	_
6	modification	_	_	NN	_	_	_	_	_
7	that	_	_	WDT	_	_	_	_	_
8	significantly	_	_	RB	_	_	_	_	_
9	increases	_	_	VBZ	_	_	_	_	_
10	during	_	_	IN	_	_	_	_	_
11	aging	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	results	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	formation	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	advanced	_	_	JJ	_	_	_	_	_
19	glycation	_	_	NN	_	_	_	_	_
20	end	_	_	NN	_	_	_	_	_
21	products	_	_	NNS	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	AGEs	_	_	NNS	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	AGEs	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	generated	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	initial	_	_	JJ	_	_	_	_	_
7	non-enzymatic	_	_	JJ	_	_	_	_	_
8	reaction	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	amino	_	_	JJ	_	_	_	_	_
11	groups	_	_	NNS	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	reactive	_	_	JJ	_	_	_	_	_
14	carbonyl	_	_	NN	_	_	_	_	_
15	groups	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	monosaccharides	_	_	NNS	_	_	_	_	_
18	known	_	_	VBN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	Maillard	_	_	NNP	_	_	_	_	_
22	reaction	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	thereby	_	_	RB	_	_	_	_	_
25	forming	_	_	VBG	_	_	_	_	_
26	Schiff-base	_	_	NNP	_	_	_	_	_
27	adducts	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	adducts	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	subsequently	_	_	RB	_	_	_	_	_
5	rearranged	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	so-called	_	_	JJ	_	_	_	_	_
8	Amadori	_	_	NNP	_	_	_	_	_
9	products	_	_	NNS	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	undergo	_	_	VBP	_	_	_	_	_
12	further	_	_	JJR	_	_	_	_	_
13	oxidation	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	dehydration	_	_	NN	_	_	_	_	_
16	reactions	_	_	NNS	_	_	_	_	_
17	leading	_	_	VBG	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	large	_	_	JJ	_	_	_	_	_
21	group	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	heterogeneous	_	_	JJ	_	_	_	_	_
24	products	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Up	_	_	IN	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	stage	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	Amadori	_	_	NNP	_	_	_	_	_
8	products	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	adducts	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	basically	_	_	RB	_	_	_	_	_
13	reversible	_	_	JJ	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Preferentially	_	_	RB	_	_	_	_	_
2	lysine	_	_	NN	_	_	_	_	_
3	residues	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	but	_	_	CC	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	other	_	_	JJ	_	_	_	_	_
8	amino	_	_	JJ	_	_	_	_	_
9	acids	_	_	NNS	_	_	_	_	_
10	including	_	_	VBG	_	_	_	_	_
11	arginine	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	histidine	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	tryptophan	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	cysteine	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	are	_	_	VBP	_	_	_	_	_
21	modified	_	_	VBN	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	glycation	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	prominent	_	_	JJ	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	well-known	_	_	JJ	_	_	_	_	_
6	AGEs	_	_	NNS	_	_	_	_	_
7	identified	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	cells	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	tissues	_	_	NNS	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	carboxymethyllysine	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	CML	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	carboxyethyllysine	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	CEL	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	pentosidine	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	desoxyglucosone	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Physiologically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	AGEs	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	formed	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	response	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	so-called	_	_	JJ	_	_	_	_	_
11	“	_	_	``	_	_	_	_	_
12	dicarbonyl	_	_	NN	_	_	_	_	_
13	stress	_	_	NN	_	_	_	_	_
14	”	_	_	''	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	given	_	_	VBN	_	_	_	_	_
17	under	_	_	IN	_	_	_	_	_
18	conditions	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	hyperglycemia	_	_	NN	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	presence	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	highly	_	_	RB	_	_	_	_	_
27	reactive	_	_	JJ	_	_	_	_	_
28	α-dicarbonyls	_	_	NNS	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	α-DCs	_	_	NNS	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	such	_	_	JJ	_	_	_	_	_
33	as	_	_	IN	_	_	_	_	_
34	glyoxal	_	_	NN	_	_	_	_	_
35	(	_	_	-LRB-	_	_	_	_	_
36	GO	_	_	NN	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	methylglyoxal	_	_	NN	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	MGO	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	or	_	_	CC	_	_	_	_	_
44	3-deoxyglucosone	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	α-DCs	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	inevitable	_	_	JJ	_	_	_	_	_
5	byproducts	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	anaerobic	_	_	JJ	_	_	_	_	_
8	glycolysis	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	lipid	_	_	NN	_	_	_	_	_
11	peroxidation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	consequence	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	induce	_	_	VBP	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	formation	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	highly	_	_	RB	_	_	_	_	_
21	stable	_	_	JJ	_	_	_	_	_
22	AGEs	_	_	NNS	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	crosslink	_	_	VBP	_	_	_	_	_
25	proteins	_	_	NNS	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	lead	_	_	VBP	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	protease-resistant	_	_	JJ	_	_	_	_	_
30	protein	_	_	NN	_	_	_	_	_
31	aggregates	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	context	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	glycation-induced	_	_	JJ	_	_	_	_	_
6	modifications	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	extracellular	_	_	JJ	_	_	_	_	_
9	matrix	_	_	NN	_	_	_	_	_
10	proteins	_	_	NNS	_	_	_	_	_
11	resulting	_	_	VBG	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	intermolecular	_	_	JJ	_	_	_	_	_
14	crosslinks	_	_	NNS	_	_	_	_	_
15	lead	_	_	VBP	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	increased	_	_	VBN	_	_	_	_	_
18	stiffness	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	tissues	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	vessels	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	affect	_	_	VB	_	_	_	_	_
25	cell	_	_	NN	_	_	_	_	_
26	migration	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	clear	_	_	JJ	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	glycation	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	AGEs	_	_	NNS	_	_	_	_	_
11	lead	_	_	VBP	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	mitochondrial	_	_	JJ	_	_	_	_	_
14	dysfunction	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	impaired	_	_	VBN	_	_	_	_	_
17	immune	_	_	JJ	_	_	_	_	_
18	responses	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Glycation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	growth	_	_	NN	_	_	_	_	_
4	factors	_	_	NNS	_	_	_	_	_
5	such	_	_	JJ	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	platelet-derived	_	_	JJ	_	_	_	_	_
8	growth	_	_	NN	_	_	_	_	_
9	factor	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	PDGF	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	insulin	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	as	_	_	RB	_	_	_	_	_
17	well	_	_	RB	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	receptors	_	_	NNS	_	_	_	_	_
20	such	_	_	JJ	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	nerve	_	_	NN	_	_	_	_	_
23	growth	_	_	NN	_	_	_	_	_
24	factor	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	NGF)-receptor	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	were	_	_	VBD	_	_	_	_	_
29	reported	_	_	VBN	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	affect	_	_	VB	_	_	_	_	_
32	signaling	_	_	NN	_	_	_	_	_
33	functions	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	AGE	_	_	NN	_	_	_	_	_
5	modification	_	_	NN	_	_	_	_	_
6	itself	_	_	PRP	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	induce	_	_	VB	_	_	_	_	_
9	signaling	_	_	VBG	_	_	_	_	_
10	mainly	_	_	RB	_	_	_	_	_
11	through	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	receptor	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	advanced	_	_	JJ	_	_	_	_	_
16	glycation	_	_	NN	_	_	_	_	_
17	end	_	_	NN	_	_	_	_	_
18	products	_	_	NNS	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	RAGE	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	multi-ligand	_	_	JJ	_	_	_	_	_
25	transmembrane	_	_	NN	_	_	_	_	_
26	receptor	_	_	NN	_	_	_	_	_
27	containing	_	_	VBG	_	_	_	_	_
28	immunoglobulin	_	_	NN	_	_	_	_	_
29	domains	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	RAGE-induced	_	_	VBN	_	_	_	_	_
2	signaling	_	_	NN	_	_	_	_	_
3	contributes	_	_	VBZ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	aging-related	_	_	JJ	_	_	_	_	_
6	inflammation	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	metabolic	_	_	JJ	_	_	_	_	_
9	diseases	_	_	NNS	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	modulation	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	multiple	_	_	JJ	_	_	_	_	_
14	pathways	_	_	NNS	_	_	_	_	_
15	including	_	_	VBG	_	_	_	_	_
16	phosphoinositide	_	_	NN	_	_	_	_	_
17	3-kinase	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	PI3K	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	Erk1/2	_	_	NNP	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	Wnt	_	_	NNP	_	_	_	_	_
25	signaling	_	_	VBG	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	outcome	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	AGEs	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	RAGE	_	_	NN	_	_	_	_	_
9	signaling	_	_	NN	_	_	_	_	_
10	appears	_	_	VBZ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	double-edged	_	_	JJ	_	_	_	_	_
15	sword	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	degenerative	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	protective	_	_	JJ	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	appears	_	_	VBZ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	true	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	respect	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	role	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Wnt	_	_	NN	_	_	_	_	_
14	signaling	_	_	VBG	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	aging	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	canonical	_	_	JJ	_	_	_	_	_
3	Wnt/β-catenin	_	_	JJ	_	_	_	_	_
4	signaling	_	_	NN	_	_	_	_	_
5	cascade	_	_	NN	_	_	_	_	_
6	acts	_	_	VBZ	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	pivotal	_	_	JJ	_	_	_	_	_
10	regulator	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	developmental	_	_	JJ	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	pathogenesis	_	_	NN	_	_	_	_	_
15	pathways	_	_	NNS	_	_	_	_	_
16	including	_	_	VBG	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	stemness	_	_	NN	_	_	_	_	_
19	maintenance/differentiation	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	carcinogenesis	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	aging-related	_	_	JJ	_	_	_	_	_
25	phenotypes	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	clear	_	_	JJ	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	role	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	Wnt	_	_	NN	_	_	_	_	_
13	pathway	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	mitochondrial	_	_	JJ	_	_	_	_	_
16	respiratory	_	_	JJ	_	_	_	_	_
17	capacity	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	metabolic	_	_	JJ	_	_	_	_	_
20	homeostasis	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	especially	_	_	RB	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	glucose	_	_	NN	_	_	_	_	_
25	metabolism	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Within	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	canonical	_	_	JJ	_	_	_	_	_
4	Wnt	_	_	NNP	_	_	_	_	_
5	signaling	_	_	VBG	_	_	_	_	_
6	pathway	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	β-catenin	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	central	_	_	JJ	_	_	_	_	_
12	player	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Normally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	excess	_	_	JJ	_	_	_	_	_
4	β-catenin	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	rapidly	_	_	RB	_	_	_	_	_
7	degraded	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ubiquitin-proteasome	_	_	JJ	_	_	_	_	_
11	pathway	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Activation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	pathway	_	_	NN	_	_	_	_	_
5	leads	_	_	VBZ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	stabilization	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	β-catenin	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	its	_	_	PRP$	_	_	_	_	_
13	accumulation	_	_	NN	_	_	_	_	_
14	within	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	cytosol	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	nucleus	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	where	_	_	WRB	_	_	_	_	_
22	it	_	_	PRP	_	_	_	_	_
23	interacts	_	_	VBZ	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	T-cell	_	_	NNP	_	_	_	_	_
26	factor/lymphoid	_	_	NN	_	_	_	_	_
27	enhancer-binding	_	_	NN	_	_	_	_	_
28	factor	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	TCF/LEF	_	_	NN	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	transcription	_	_	NN	_	_	_	_	_
33	factors	_	_	NNS	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	thereby	_	_	RB	_	_	_	_	_
36	regulates	_	_	VBZ	_	_	_	_	_
37	transcription	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	multiple	_	_	JJ	_	_	_	_	_
40	target	_	_	NN	_	_	_	_	_
41	genes	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	years	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	multitude	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	other	_	_	JJ	_	_	_	_	_
9	crosstalks	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	co-operations	_	_	NNS	_	_	_	_	_
12	affecting	_	_	VBG	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	pathway	_	_	NN	_	_	_	_	_
15	have	_	_	VBP	_	_	_	_	_
16	been	_	_	VBN	_	_	_	_	_
17	identified	_	_	VBN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	variants	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	TCF-4	_	_	NNP	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	TCF7L2	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	gene	_	_	NN	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	associated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	increased	_	_	VBN	_	_	_	_	_
16	risk	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	type	_	_	NN	_	_	_	_	_
19	2	_	_	CD	_	_	_	_	_
20	diabetes	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Based	_	_	VBN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	that	_	_	DT	_	_	_	_	_
4	knowledge	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	hypothesized	_	_	VBD	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	Wnt	_	_	NN	_	_	_	_	_
10	ligands	_	_	NNS	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	secreted	_	_	VBN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	cysteine-rich	_	_	JJ	_	_	_	_	_
15	proteins	_	_	NNS	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	susceptible	_	_	JJ	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	α-DC-mediated	_	_	JJ	_	_	_	_	_
20	modifications	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	that	_	_	IN	_	_	_	_	_
23	glycation	_	_	NN	_	_	_	_	_
24	might	_	_	MD	_	_	_	_	_
25	modulate	_	_	VB	_	_	_	_	_
26	their	_	_	PRP$	_	_	_	_	_
27	signaling	_	_	VBG	_	_	_	_	_
28	activities	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	decided	_	_	VBD	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	use	_	_	VB	_	_	_	_	_
9	Wnt3a	_	_	NNP	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	proof	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	principle	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	study	_	_	VB	_	_	_	_	_
17	effects	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	GO-treatment	_	_	NN	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	Wnt3a	_	_	NNP	_	_	_	_	_
22	conditioned	_	_	VBN	_	_	_	_	_
23	medium	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	Wnt3a	_	_	NNP	_	_	_	_	_
26	CM	_	_	NNP	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	observed	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	ratio	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	phospho-β-catenin	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	total	_	_	JJ	_	_	_	_	_
10	β-catenin	_	_	NN	_	_	_	_	_
11	increased	_	_	VBD	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	further	_	_	JJR	_	_	_	_	_
4	consequence	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Wnt3a-induced	_	_	JJ	_	_	_	_	_
7	activation	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	β-catenin/TCF	_	_	NNP	_	_	_	_	_
11	transcription	_	_	NN	_	_	_	_	_
12	complex	_	_	NN	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	reduced	_	_	VBN	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	shown	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	reporter	_	_	NN	_	_	_	_	_
19	gene	_	_	NN	_	_	_	_	_
20	assays	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	decreased	_	_	VBN	_	_	_	_	_
24	expression	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	endogenous	_	_	JJ	_	_	_	_	_
27	Wnt	_	_	NN	_	_	_	_	_
28	target	_	_	NN	_	_	_	_	_
29	genes	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_

